(Q53838690)

20 May 2018

title

Combination immunotherapy with prostate GVAX and ipilimumab: safety and toxicity. (English)

1 reference

20 May 2018

1 reference

Dev Karan

1

1 reference

20 May 2018

Peter Van Veldhuizen

series ordinal

2

1 reference

20 May 2018

publication date

1 June 2012

1 reference

20 May 2018

published in

Immunotherapy

1 reference

20 May 2018

volume

4

1 reference

20 May 2018

issue

6

1 reference

20 May 2018

page(s)

577-580

1 reference

20 May 2018

cites work

Global cancer statistics

1 reference

Expanding treatment options for metastatic prostate cancer

21 January 2018

1 reference

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

21 January 2018

1 reference

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

Cancer immunotherapy comes of age

21 January 2018

1 reference

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

21 January 2018

1 reference

Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer

21 January 2018

1 reference

Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues

21 January 2018

1 reference

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

21 January 2018

1 reference

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade

21 January 2018

1 reference

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

21 January 2018

1 reference

GM-CSF-induced CD11c+CD8a--dendritic cells facilitate Foxp3+ and IL-10+ regulatory T cell expansion resulting in suppression of autoimmune thyroiditis

21 January 2018

1 reference

Effect of granulocyte-macrophage colony-stimulating factor on the immune response of circulating monocytes after severe trauma

21 January 2018

1 reference

HLA-DR regulation and the influence of GM-CSF on transcription, surface expression and shedding.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.12.53

1 reference

20 May 2018

1 reference

20 May 2018